Previous 10 | Next 10 |
2023-11-20 13:54:04 ET BioLineRx Ltd. (BLRX) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - President of BioLineRx USA Mali Zeevi - CFO ...
2023-11-20 08:24:45 ET Losers: Syntec Optics Holdings ( OPTX ) -15% . Safe and Green Development Corp ( SGD ) -14% . Plus Therapeutics ( PSTV ) -14% reports new interim reSPECT-GBM phase 2 trial data at the society for NeuroOncology annual meeting. ...
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates PR Newswire - Received FDA Approval of APHEXDA® (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Auto...
AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...
BioLineRx Ltd. (BLRX) is expected to report $-0.18 for Q3 2023
2023-11-19 08:00:00 ET Even with the holiday-shortened Thanksgiving week, several prominent companies are set to unveil their quarterly results next week. The docket includes tech giant Nvidia ( NASDAQ: NVDA ), as well as Zoom Video ( NASDAQ: ZM ), HP Inc. ( NYSE: HPQ ...
2023-11-17 12:56:05 ET More on biolinerx Assessing BioLineRx As A Buy After Drug Approval BioLineRx Ltd. (BLRX) Q2 2023 Earnings Call Transcript BioLineRx announces closing of exclusive license agreement with GloriaBio BioLineRx gains after winning first FDA ...
2023-11-17 09:47:47 ET Major earnings expected before the bell on Monday include: BioLineRx ( BLRX ) Niu Technologies ( NIU ) VEON ( VEON ) Zepp Health ( ZEPP ) For Seeking Alpha's earnings season calendar, click here . For further detai...
BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 PR Newswire - Management to Hold Conference Call at 10:00 a.m. EST - TEL AVIV, Israel , Nov. 13, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial sta...
2023-11-05 02:15:00 ET Summary Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA. BioLineRx, an Israeli biotech, out-licensed China rights to a stem cell mobilizer for multiple myeloma and stem cell disease...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...